

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450



PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/520,271
Filing Date	January 14, 2005
First Named Inventor	Hadi ASLAN et al
Group Art Unit	1633
Examiner Name	WEHBE, ANNE MARIE SABRINA

Sheet	2	Of	3	Attorney Docket Number	28921
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
/AW/	6	Clarke et al. "Mesenchymal Cell Precursors From Human Bone Marrow Have A Phenotype That Is Distinct From Cultured Mesenchymal Cells and Are Exclusively Present in A Small Subset of CD451 ⁺ SH2+ Cells", Blood, 98(11 Part 1): 85a, 2001. Abstract # 355.			
	7	Quirici et al. "Isolation of Bone Marrow Mesenchymal Stem Cells by Anti-Nerve Growth Factor Receptor Antibodies", Experimental Hematology, 30(7): 783-791, 2000.			
	8	Devine et al. "Mesenchymal Stem Cells Are Capable of Homing to the Bone Marrow of Non-Human Primates Following Systemic Infusion", Experimental Hematology, 29(2): 244-255, 2001.			
	9	Caplan et al. "Mesenchymal Stem Cells: Building Block for Molecular Medicine in the 21st Century", Trends in Molecular Medicine, 7(6): 259-264, 2001.			
	10	Gronthos et al. "The Growth Factor Requirements of STRO-1- Human Bone Marrow Stromal Precursors Serum-Deprived Conditions In Vitro", Blood, 85(4): 992-940, 1995.			
	11	Fridenshtein "Stromal Bone Marrow Cells and the Hematopoietic Microenvironment", Arkh Patol, 44(10): 3-11, 1982. Abstract.			
	12	Haynesworth et al. "Characterization of Cells with Osteogenic Potential from Human Marrow", Bone, 13: 81-88, 1992.			
	13	Horowitz et al. "Transplantability and Therapeutic Effects of Bone Marrow-Derived Mesenchymal Cells in Children with Osteogenesis Imperfecta", Nature Medicine, 5(3): 309-313, 1999.			
	14	Kadiyala et al. "Culture Expanded Canine Mesenchymal Stem Cells Possess Osteochondrogenic Potential In Vivo and In Vitro", Cell Transplantation, 6(2): 125-134, 1997.			
	15	Krebsbach et al. "Repair of Craniotomy Defects Using Bone Marrow Stromal Cells", Transplantation, 66(10): 1272-1278, 1998.			
	16	Keunmyoung et al. "Human Mesenchymal Stem Cells Maintain Transgene Expression during Expansion and Differentiation", Molecular Therapy, 3(6), 2001.			857-866
	17	Liechty et al. "Human mesenchymal stem cells engraft and demonstrate sitespecific differentiation after in utero transplantation in sheep", Nature Medicine, 6(11): 1282-1286, 2000.			
	18	Mackay et al. "Chondrogenic Differentiation of Cultured Human Mesenchymal Stem Cells from Marrow", Tissue Engineering, 4(4): 415-428, 1998.			
	19	Majumdar et al. "Isolation, Characterization, and Chondrogenic Potential of Human Bone Marrow-Derived Multipotential Stromal Cells, Journal of Cellular Physiology, 185: 98-106, 2000.			
	20	Majumdar et al. "Cutting Edge Communication - Human Marrow-Derived Mesenchymal Stem Cells (MSCs) Express Hematopoietic Cytokines and Support Long-Term Hematopoiesis when Differentiated Toward Stromal and Osteogenic Lineages", Journal of Hematotherapy & Stem Cell Research, 9: 841-848, 2000.			
	21	Pittenger et al. "Multilineage Potential of Adult Human Mesenchymal Stem Cells", Science, 284: 143-147, 1999.			
	22	Toma et al. "Human Mesenchymal Stem Cells Differentiate to a Cardiomyocyte Phenotype in the Adult Murine Heart", Circulation, 1/8: 93-98, 2002.			
↓	23	Turgeman et al. "Engineered Human Mesenchymal Stem cells: a Novel Platform for Skeletal Cell Mediated Gene Therapy", The Journal of Gene Medicine, 3: 240-251, 2001.			

/AW/	24	Yoo et al. "The Cohondrogenic Potential of Human Bone-Marrow-Derived Mesenchymal Progenitor Cells", Journal of Bone and Joint Surgery, 80-A(12): 1745-1757, 1998.	
/AW/	25	Young et al. "Use of Mesenchymal Stem Cells in a Collagen Matrix for Achilles Tendon Repair", Journal of the Orthopaedic Research, 16: 406-413, 1998.	
/AW/	26	Pittenger et al. "Human Mesenchymal Stem Cells Can Be Directed Into chondrocytes, Adipocytes and Osteocytes" Mol. Biol. Cell. 1996 &:305a. - Abstract only.	

Signature	/Anne Marie Wehbe/ (10/12/2007)	Considered	10/12/2007
-----------	---------------------------------	------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹. Applicant's unique citation designation number (optional). ². Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.